ライフサイエンスコーパス: sequential treatment

1 forkhead box M1, which was not observed with sequential treatment.

2 moradiotherapy now seems more effective than sequential treatment.

3 hese were not as pronounced as observed with sequential treatment.

4 After sequential treatment, 11 (85%) of 13 patients achieved a

5 Ten-day Levofloxacin-based sequential treatment achieved inadequate efficacy rate (

6 including an AI as primary monotherapy or as sequential treatment after 2 to 3 years of tamoxifen yie

7 treatment, either as up-front therapy or as sequential treatment after tamoxifen.

8 Depression subjects were drawn from the Sequential Treatment Alternatives to Relieve Depression

9 2 in one (0.8%) of 130 patients who received sequential treatment and four (2.9%) of 137 patients who

10 A combination of novel drugs with ASCT in a sequential treatment approach can attain long-term survi

11 egrate the novel agents for CLL therapy into sequential treatment approaches in the near future.

12 high-quality studies with 728 patients in a sequential treatment arm and 682 in a control treatment

13 Apart from sequential treatment assignment, reduced adherence was a

14 rance of the bacterium can be achieved using sequential treatments at antibiotic dosages so low that

15 tment of HSV-1 virions with pH 5 or multiple sequential treatments at pH 5 followed by neutral pH cau

16 hemical expansion of graphite is achieved by sequential treatment, beginning with the established met

17 lls showed an additive survival effect after sequential treatment, but a toxic effect was observed af

18 We have identified a safe and active sequential treatment combination of azacitidine and lena

19 5 years of an aromatase inhibitor alone, and sequential treatment consisting of tamoxifen with cross

20 horts in oncology and other fields requiring sequential treatment decisions.

21 A screen of 136 96-h-long sequential treatments determined five of these that coul

22 neic hematopoietic cell transplantation in 2 sequential treatment eras, to determine whether those tr

23 sible to assess IRIS in more patients in the sequential treatment group (n = 74) than in the late int

24 weeks after tuberculosis therapy completion (sequential treatment group).

25 n the early integrated, late integrated, and sequential treatment groups, respectively.

26 n the early integrated, late integrated, and sequential treatment groups, respectively.

27 .5%, 95% CI 47.8-64.9) patients who received sequential treatment had a pathological complete respons

28 resulted in increased survival when used as sequential treatment in both breast cancer and NSCLC.

29 ganciclovir (GCV) was less efficacious than sequential treatment in human DU145 prostate carcinoma c

30 Sequential treatments in O(2) and H(2) formed small (app

31 of two synergistic antibiotics to so-called sequential treatments in which the choice of antibiotic

32 This sequential treatment induced phosphorylation of p53 at S

33 Sequential treatments involving tamoxifen and letrozole

34 RPM as a sequential treatment markedly inhibited mRNA levels codi

35 Sequential treatment of 2,3-dichloropropene with magnesi

36 Sequential treatment of a conformationally biased allyli

37 Here, we show that sequential treatment of AML blasts with decitabine follo

38 Purpose The Sequential Treatment of CD20-Positive Posttransplant Lym

39 The method is based on the sequential treatment of cell walls with specific hydroly

40 Sequential treatment of decitabine followed by selinexor

41 with PEGylated IFN-alpha, and patients with sequential treatment of Entecavior and PEGylated IFN-alp

42 Importantly, sequential treatment of HL-60 cells with etoposide, Ara-

43 Furthermore, sequential treatment of hPSCs with glycogen synthase kin

44 silencing of this HSC genetic program by the sequential treatment of human cord blood CD34(+) cells w

45 Sequential treatment of macrophages with multiple cytoki

46 The sequential treatment of nude mice with chemotherapeutic

47 tudied the efficacy of administering a novel sequential treatment of parenteral ACK2, an antibody tha

48 Importantly, sequential treatment of PC-3, DU145, and LNCaP cells wit

49 The sequential treatment of peanuts by ultrasonication-tryps

50 Furthermore, sequential treatment of PMF CD34(+) cells but not normal

51 The sequential treatment of PMF CD34+ cells with the chromat

52 ions, was demonstrated experimentally by the sequential treatment of spirochetes with Fab-CB2 and mon

53 d a study to assess whether or not selective sequential treatment of the more diseased upper lobe seg

54 tion of activity by dithiothreitol following sequential treatment of the V-ATPase with SNG and N-ethy

55 stic reactivation of CDKN2A is observed upon sequential treatment of Tu159 cells with both 5-aza-dC a

56 of the leaderless polypeptide IL-1 beta, but sequential treatment of wild-type, but not P2X(7)R-defic

57 Sequential treatments of the hair bundles with BAPTA and

58 ger (18.1 versus 10.3 weeks) to respond to a sequential treatment paradigm (adding a selective seroto

59 re critical to understanding the benefits of sequential treatment (parathyroid hormone followed by an

60 Toxicity management and, for sequential treatments, patient and physician awareness,

61 veloping a novel methodology to assess these sequential treatment processes.

62 The sequential treatment produced the greatest induction of

63 east cancer and may be feasible as part of a sequential treatment program including anthracyclines.

64 Patients randomly assigned to sequential treatment received fluorouracil 500 mg/m(2),

65 This sequential treatment regimen is highly effective as fron

66 pproved antiretroviral agents, the number of sequential treatment regimens that will be effective for

67 ersonal psychotherapy and an 8-week delay in sequential treatment response among women with recurrent

68 orescent protein-alpha-tubulin revealed that sequential treatment resulted in G2 checkpoint abrogatio

69 A sequential treatment schedule increases toxicity but may

70 Whole-liver treatment was achieved with sequential treatment sessions in most patients, with sel

71 Sensitivity analyses suggest that sequential treatment strategies optimized 10-year diseas

72 The authors evaluated a sequential treatment strategy of fluoxetine and relapse-

73 PFS is promising, and this sequential treatment strategy should be further investig

74 We explored a sequential treatment strategy to allow safe delivery of

75 be carefully deployed and not all sublethal sequential treatments succeed.

76 heckpoint abrogation and mitotic death after sequential treatment, this was not accompanied by an inc

77 Comparison of sequential treatments to letrozole monotherapy included

78 In contrast, sequential treatment was antagonistic and had a minimal

79 tion rate obtained with Clarithromycin-based sequential treatment was significantly higher than with

80 and HCT8 colorectal carcinoma cells, whereas sequential treatments were additive at best.

81 Sequential treatments were associated with higher rates

82 rs of tamoxifen or letrozole monotherapy, or sequential treatment with 2 years of one of these drugs

83 Last, sequential treatment with 5-aza-2'-deoxycytidine followe

84 e influenced in response to thapsigargin and sequential treatment with acetylcholine.

85 Survivors of sequential treatment with Adriamycin and FUdR (MCF-7 A/F

86 Furthermore, differential and sequential treatment with blocking antibodies directed a

87 Twenty patients received sequential treatment with both dasatinib and nilotinib f

88 that this homing defect can be corrected by sequential treatment with chromatin-modifying agents.

89 Sequential treatment with CMAs, therefore, represents a

90 2V617F(+) HPCs and SRCs can be eliminated by sequential treatment with CMAs.

91 al of 226 patients were randomly assigned to sequential treatment with cytarabine and infusional DNR

92 Sequential treatment with decitabine and cytarabine was

93 The 3T3-L1 adipocytes differentiated by sequential treatment with dex and IBMX displayed insulin

94 Sequential treatment with Epo B followed by FP induced s

95 s attenuated the lordosis response following sequential treatment with estradiol and progesterone.

96 ferative Disorder (PTLD-1) trial established sequential treatment with four cycles of rituximab follo

97 Laboratory data have suggested that sequential treatment with granulocyte-macrophage/colony-

98 imerized to its trans-fused counterpart 2 on sequential treatment with iodosylbenzene then sodium bor

99 bstantial intraocular bleeding compared with sequential treatment with low-molecular-weight heparin a

100 06 samples from 33 patients who had received sequential treatment with multiple TKIs and had experien

101 Furthermore, sequential treatment with paclitaxel followed by ET-743

102 E14 ES cells into mature granule neurons by sequential treatment with secreted factors (WNT1, FGF8,

103 present in J774A.1 cells, was eliminated by sequential treatment with small hairpin RNA expressing l

104 Sequential treatment with SN-38 followed by UCN-01 resul

105 dine (26) with selenium dioxide, followed by sequential treatment with sodium borohydride, methanesul

106 Following sequential treatment with sodium butyrate and the carcin

107 The ordered sequential treatment with SWCNTs and H(2)O(2) or NaOCl r

108 trial confirm that both exemestane alone and sequential treatment with tamoxifen followed by exemesta

109 genotypes in CML patients who relapsed after sequential treatment with the ABL inhibitors imatinib an

110 We have explored the effects of the sequential treatment with the DNA methyltransferase inhi

111 Sequential treatment with the F(ab')2 fragment of anti-F

112 ffered external solution was recorded during sequential treatment with the potassium ionophore valino

113 In contrast, sequential treatment with these two agents in either ord

114 preliminarily assess the clinical safety of sequential treatment with tirofiban or eptifibatide foll

115 Sequential treatment with two different amino acids sepa

116 Other samples of MV were subjected to sequential treatments with enzymes, salt solutions, and

117 th TRAIL-sensitive and -resistant cells upon sequential treatments with HDAC inhibitors followed by T

118 Thus, the sequential treatments with HDAC inhibitors followed by T

119 Sequential treatments with heat and chymotrypsin caused